Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omega Pure is an omega-3 fatty acid supplement consisting of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). It was evaluated as an investigational therapy in a Phase 2 clinical trial (NCT00691288) sponsored by The Hospital for Sick Children for the management of hypertriglyceridemia in pediatric patients with HIV who are undergoing highly active antiretroviral therapy (HAART). The mechanism of action involves the reduction of hepatic triglyceride synthesis, likely through the inhibition of enzymes such as diacylglycerol O-acyltransferase and the activation of peroxisome proliferator-activated receptor alpha (PPAR-alpha), which enhances fatty acid oxidation and triglyceride clearance via lipoprotein lipase activation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on omega-3 fatty acids (SickKids).